相关实验视频

Updated: Jul 17, 2025

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Establishment of a Primary Culture of Patient-derived Soft Tissue Sarcoma

Published on: April 11, 2018

精准医学时代的肉瘤护理

Karin Wallander¹, Ingegerd Öfverholm¹, Kjetil Boye²

¹Oncology-Pathology, Karolinska Institutet, Stockholm, Sweden.

Journal of internal medicine

|August 29, 2023

概括

分子分析通过识别遗传标记来提高肉瘤诊断和护理. 这些标记物有助于分类亚型,预测治疗反应和确定预后,补充了传统的组织病理学.

科学领域:

在瘤学瘤学.
遗传学是一个遗传学.
病理学病理学病理学

背景情况:

传统上,肉瘤的分类依赖于组织病理学.
分子分析对于准确的肉瘤诊断和患者护理越来越重要.
对肉瘤基因组学知识的不断增长揭示了关键的遗传事件和治疗点.

研究的目的:

对临床肉瘤管理的诊断,治疗和预后分子标记进行审查.
突出基因发现在支持或完善组织病理学诊断中的作用.
讨论新型测序技术在肉瘤诊断中的整合.

主要方法:

关于肉瘤分子标记物的当前文献的综述.
分析特定的遗传融合 (例如,SYT::SSX) 和型异常.
对治疗预测 (例如,GIST) 和预后 (例如,单一纤维性瘤) 的分子标记物的检查.

主要成果:

特定的遗传融合对某些类型的瘤亚型具有病原性.
复杂的型和基因放大 (MDM2/CDK4) 提供诊断信息.
分子标志物为GIST治疗提供了预测价值,并在单一纤维性瘤中提供了预后见解.

结论:

分子标记物是瘤诊断和护理中对组织病理学的必要补充物.
了解基因组发现的背景和局限性,以及组织形态学,对于解释至关重要.
预计在肉瘤中心将越来越多地使用大规模并行测序.

关键词:

分子病理学分子病理学精准医学是一门精准医学.肉瘤肉瘤是一种肉瘤.

更多相关视频

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Integration of Wet and Dry Bench Processes Optimizes Targeted Next-generation Sequencing of Low-quality and Low-quantity Tumor Biopsies

Published on: April 11, 2016

The In ovo CAM-assay as a Xenograft Model for Sarcoma

The In ovo CAM-assay as a Xenograft Model for Sarcoma

Published on: July 17, 2013

相关概念视频

Combination Therapies and Personalized Medicine

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...

Targeted Cancer Therapies

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...

Tumor Progression

Tumor Progression

Tumor progression is a phenomenon where the pre-formed tumor acquires successive mutations to become clinically more aggressive and malignant. In the 1950s, Foulds first described the stepwise progression of cancer cells through successive stages.
Colon cancer is one of the best-documented examples of tumor progression. Early mutation in the APC gene in colon cells causes a small growth on the colon wall called a polyp. With time, this polyp grows into a benign, pre-cancerous tumor. Further...

Cancer Survival Analysis

Cancer Survival Analysis

Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...

Tumor Immunotherapy

Tumor Immunotherapy

Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.

Treatment Resistant Cancers

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...